Smith, Moore & Co. Precigen, Inc. Transaction History

Smith, Moore & Co.

$1.03 Billion
Q3 2024

A detailed history of Smith, Moore & Co. transactions in Precigen, Inc. stock. As of the latest transaction made, Smith, Moore & Co. holds 15,000 shares of PGEN stock, worth $12,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,000

Holding current value

$12,300

% of portfolio

0.0%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 12, 2024	BUY	$0.91 - $1.88 $13,650 - $28,200	15,000 New	15,000 $14,000

Others Institutions Holding PGEN

# of Institutions

144

Shares Held

159M

Call Options Held

232K

Put Options Held

69K

Third Security, LLC

83.5M
Shares

$68.4 Million
73.5% of portfolio
Patient Capital Management, LLC Baltimore, MD

17.9M
Shares

$14.7 Million
0.92% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

10.9M
Shares

$8.91 Million
0.02% of portfolio
Black Rock Inc. New York, NY

10.2M
Shares

$8.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.33M
Shares

$6.83 Million
0.0% of portfolio

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $171M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.

Account